Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Bicara Therapeutics reported Q3 2026 financial results, ending the period with $442.3 million in cash and marketable securities. The company achieved substantial enrollment in its FORTIFI-HN01 pivotal trial for head and neck cancer, with topline interim results expected in mid-2027. Management expects current cash reserves to fund operations into the first half of 2029.
Term
Q3 2026
“Ficerafusp alfa was purpose-built for HPV-negative head and neck cancer by inhibiting both EGFR and TGF-β, and the depth and durability of response it has demonstrated to date continue to set it apart in a disease with significant unmet need.”
Ryan Cohlhepp, President, Interim Chief Executive Officer and Chief Operating Officer
“Achieving substantial enrollment in the FORTIFI-HN01 pivotal trial reflects strong execution by our team and growing recognition among investigators that HPV-negative disease requires a targeted approach grounded in its distinct biology.”
Ryan Cohlhepp, President, Interim Chief Executive Officer and Chief Operating Officer
RadNet reported record third-quarter financial results for 2026, with total revenue increasing 22.1% year-over-year to $638.3 million. The company saw strong growth in advanced imaging volumes and its Digital Health segment, leading management to revise its full-year 2026 guidance ranges upward for revenue, Adjusted EBITDA, and free cash flow.
Term
Q3 2026
“We delivered record quarterly Revenue and Adjusted EBITDA (1) in the third quarter. Total Company Revenue grew 22.1% and Adjusted EBITDA (1) grew 23.8% compared with last year’s third quarter, and Adjusted EBITDA (1) margin expanded 23 basis points.”
Dr. Howard Berger, President and Chief Executive Officer of RadNet
“With strong performance across nearly every part of the core imaging center business, we are again raising certain guidance ranges in anticipation that full-year results will exceed both our original expectations and the revised ranges issued in conjunction with first and second quarter 2026 results.”
Dr. Howard Berger, President and Chief Executive Officer of RadNet
CorMedix Signs $145M M&A Deal with Heron Therapeutics, Inc.
CorMedix Inc. has entered into a definitive agreement to acquire substantially all assets of Heron Therapeutics for $145 million in cash and 14,583,333 shares of common stock. The deal adds four commercial-stage products (ZYNRELEF, APONVIE, CINVANTI, and SUSTOL) to CorMedix's institutional care portfolio and includes up to $55 million in potential earn-out payments. To fund the transaction, CorMedix secured a new $75 million senior secured term loan facility from Pharmakon Advisors.
Air Industries Group reported significantly improved Q3 2026 financial results, with net sales increasing 41.1% to $14.6 million and net income reaching $0.9 million compared to a loss in the prior year. The company noted that results were impacted by $0.5 million in expenses related to its pending merger with Tenax Aerospace Acquisition, LLC.
Matador Resources Insider Paul W. Harvey Buys $26.4K of Stock
Paul W. Harvey bought 500 shares of Matador Resources Co at $52.72 a share, worth $26.4K in total on Nov 5, 2026. Shares held after the trade: 33,121 (+1.5%).
Matador Resources Chairman and CEO Joseph Wm Foran Buys $257K of Stock
Joseph Wm Foran, Chairman and CEO, bought 5,000 shares of Matador Resources Co at $51.36 a share, worth $257K in total on Nov 5, 2026. Shares held after the trade: 9,772 (+104.8%).
Heron Therapeutics Divestiture to CorMedix Inc. for $145M
Heron Therapeutics has entered into a definitive agreement to sell substantially all of its assets to CorMedix Inc. for $145 million in cash and 14,583,333 shares of CorMedix common stock. The deal includes Heron's commercial portfolio (ZYNRELEF, APONVIE, CINVANTI, and SUSTOL) and provides for up to $55 million in potential earn-out payments plus royalties. Heron will remain a standalone public company, using the proceeds to repay its existing debt and evaluate new strategic investments.
Popular, Inc. updated its Q3 2026 financial results to recognize a $38 million additional provision for credit losses as a subsequent event. The adjustment stems from a quick service restaurant borrower filing for Chapter 11 bankruptcy, resulting in a decrease in previously reported net income and diluted EPS.
ImmunityBio reported Q3 2026 net product revenue of $48.7 million, a 53% increase year-over-year, driven by the adoption of ANKTIVA in the U.S. The company also highlighted a recent FDA label expansion for ANKTIVA and positive topline results from its QUILT-2.005 trial in BCG-naïve bladder cancer patients.
Roivant Sciences Ltd. reported 724,561,460 common shares outstanding as of November 3, 2026. The filing includes condensed consolidated financial statements for the three and six months ended September 30, 2026, and highlights risks related to biopharmaceutical product development, capital allocation, and its 'Vant' structure.
Viridian Therapeutics, Inc.\DE Clinical Trial Data
Viridian Therapeutics announced positive Phase 1 clinical trial results for VRDN-008, a half-life extended FcRn inhibitor, which demonstrated a 74% peak reduction in IgG and a half-life 5-6 times longer than first-generation fragments. The data supports a potential best-in-class every-eight-week subcutaneous dosing regimen, and the company plans to initiate a pivotal trial in myasthenia gravis in mid-2027.
For the nine months ended September 30, 2026, AN2 Therapeutics reported a net loss of $26.2 million, a slight improvement from the $26.5 million loss in the prior year. Total assets increased to $82.0 million from $62.0 million at year-end 2025, primarily driven by an increase in short-term and long-term investments following a private placement of common stock.
Popular, Inc. reported a significant increase in debt securities available-for-sale, rising from $20.6 billion at year-end 2025 to $23.4 billion as of September 30, 2026. Conversely, debt securities held-to-maturity decreased from $7.3 billion to $5.5 billion during the same period. The company remains a large accelerated filer with over 62 million shares of common stock outstanding as of November 4, 2026.
AN2 Therapeutics reported financial results for the third quarter of 2026, highlighting a net loss of $11.4 million and a cash position of $51.4 million. The company is advancing its clinical pipeline, including the expected year-end enrollment initiation for its Phase 2 study of epetraborole in polycythemia vera and the selection of a new development candidate for hypophosphatasia.
Term
Q3 2026
“The third quarter was marked by continued execution across our clinical pipeline and meaningful progress in expanding the opportunities enabled by our boron chemistry platform. With FDA IND clearance for epetraborole in polycythemia vera, we now have the necessary regulatory clearances from all planned jurisdictions for our global Phase 2 study and are advancing start up activities.”
Eric Easom, Co-Founder, Chairman, President and CEO
“Beyond our clinical stage pipeline, the selection of AN2-504661 for HPP as our second development candidate this year, further demonstrates the productivity of our research organization and the potential of our boron chemistry platform to generate differentiated therapies across multiple disease areas.”
Eric Easom, Co-Founder, Chairman, President and CEO
The Goodyear Tire & Rubber Company appointed Director Roger J. Wood as Interim CEO and President, effective November 8, 2026, following the immediate departure of Mark W. Stewart. Wood will receive a monthly salary of $310,000 and monthly RSU grants valued at $1 million while the board conducts a search for a permanent successor. Stewart's departure was classified as a termination 'other than for Cause' under the company's executive severance plan.
Azora Therapeutics appointed Aida Habtezion, M.D., Paul Hastings, and Thomas Soloway to its Board of Directors. The appointments include the reconstitution of the board's audit, compensation, and nominating committees, with Mr. Soloway serving as audit committee chair. All three new directors were determined to be independent under Nasdaq listing standards.
Netcapital Inc. received an extension from Nasdaq to regain compliance with Listing Rule 5250(c)(1) regarding delinquent periodic reports. The company has been granted until February 9, 2027, to file its Form 10-K for the fiscal year ended April 30, 2026, and its Form 10-Q for the quarter ended July 31, 2026. Failure to meet this deadline will result in a delisting notification, which the company may then appeal.
INOVIO Pharmaceuticals entered into an underwriting agreement for a public offering of 58,747,235 shares of common stock and 12,681,337 pre-funded warrants. The underwriters fully exercised their option to purchase an additional 10,714,285 shares, bringing expected net proceeds to approximately $80.5 million. The capital will be used to support the company's development and commercialization of DNA medicines.
Atea Pharmaceuticals $200M Debt Financing with Hercules Capital, Inc.
Atea Pharmaceuticals entered into a $200 million senior secured term loan facility with Hercules Capital, with an initial $65 million drawn at closing. Additional tranches are available upon achieving clinical and commercial milestones related to the bemnifosbuvir and ruzasvir (BEM/RZR) program. The facility matures in November 2031 and carries a floating interest rate starting at a minimum of 9.35%.
Ocular Therapeutix appointed Riad Sherif, M.D., to its Board of Directors as a Class I member, effective November 6, 2026. Dr. Sherif, currently the CEO of Oculis Holding AG and a former Alcon executive, received an initial equity grant of 88,000 stock options and 28,000 restricted stock units as part of his appointment.
Silexion Therapeutics announced a 1-for-24 reverse share split of its ordinary shares, effective after the market close on November 10, 2026. The split is intended to help the company regain compliance with Nasdaq's $1.00 minimum bid price requirement. Trading on a split-adjusted basis will begin on November 11, 2026, under the existing ticker symbol SLXN.
Immunovant reported a net loss of $97.2 million for the quarter ended September 30, 2026, compared to $126.5 million in the prior year period. The company maintained a strong liquidity position with $722.3 million in cash and cash equivalents, while research and development expenses remained the primary driver of operating costs at $85.0 million for the quarter.
Tonix Pharmaceuticals reported Q3 2026 financial results, highlighted by $15 million in net sales for TONMYA, representing a 37% increase over the prior quarter. The company expanded its sales force to 150 representatives and secured major managed Medicare agreements covering an additional 30 million lives. As of September 30, 2026, the company held approximately $163 million in cash and cash equivalents.
Term
Q3 2026
“We delivered another strong quarter for TONMYA, with net sales up 37% over the second quarter. Total prescriptions, new prescriptions, and refills also increased. Payer access expanded to include two commercial group purchasing organization (GPO) agreements, two managed Medicare agreements, and Medicaid access in almost every state.”
Seth Lederman, M.D., President and Chief Executive Officer
“In addition to TONMYA’s growth, we are focused on our core clinical priorities. Our priorities include advancing TNX-102 SL in major depressive disorder (MDD), TNX-4800 for Lyme disease prevention, and the investigator-initiated study of TNX-1500 (mosdaprubart) to prevent kidney transplant rejection.”
Seth Lederman, M.D., President and Chief Executive Officer
Cullinan Therapeutics announced positive interim Phase 1b/2a clinical data for velinotamig in patients with refractory systemic lupus erythematosus (SLE). The data showed that 8 of 9 evaluable patients achieved clinically meaningful reductions in disease activity, with 4 of 7 patients with high baseline proteinuria achieving a complete renal response. The therapy demonstrated a favorable safety profile with no Grade 3 or higher cytokine release syndrome or neurotoxicity.
Faeth Therapeutics reported positive topline Phase 2 results from its PIK-201 trial evaluating PIKTOR in combination with paclitaxel for advanced endometrial cancer. The trial achieved a 33% confirmed objective response rate (ORR) and a median progression-free survival of 7.4 months, supporting the company's plan to advance the program into a Phase 3 registrational trial.
Ocular Therapeutix reported a decrease in cash and cash equivalents to $530.6 million as of September 30, 2026, compared to $737.1 million at year-end 2025. Total assets decreased to $605.6 million, while total liabilities increased slightly to $164.7 million. The company is currently focused on Phase 3 clinical trials for AXPAXLI in wet AMD and NPDR.
FACT II Acquisition Corp. is seeking shareholder approval to extend its business combination deadline from November 27, 2026, to November 25, 2027. In connection with this, the company and its sponsor intend to enter into non-redemption agreements with investors to maintain funds in the trust account, which currently holds approximately $189.2 million.
Roivant Sciences reported financial results for its second fiscal quarter ended September 30, 2026, highlighted by $31.0 million in net product revenue from the first five weeks of the LISRAYA launch. The company also announced positive clinical data for IMVT-1402 in rheumatoid arthritis and brepocitinib in non-infectious uveitis, ending the period with $4.2 billion in cash and marketable securities.
Term
Q2 2026
“This quarter has marked a major transition for Roivant. LISRAYA is now commercially available to patients and we are off to a strong start, with $31.0 million in net product revenue in the first 5 weeks of launch – reflecting strong early patient and prescriber demand.”
Matt Gline, CEO of Roivant
“Today we are thrilled to announce that IMVT-1402 succeeded in Immunovant’s study in difficult-to-treat late line rheumatoid arthritis – IMVT-1402 at the 600 mg dose met the primary endpoint in Period 2, and the broader data support its potential to maintain and deepen responses in patients who have failed multiple advanced therapies and who are in need of new options.”
Aura Biosciences reported a significant increase in net loss to $111.4 million for the nine months ended September 30, 2026, driven by rising R&D and G&A expenses. Despite the loss, the company strengthened its balance sheet through a follow-on offering, ending the period with $303.1 million in current assets compared to $149.7 million at the end of 2025.
Powerfleet reported record second quarter fiscal 2027 revenue of $115.7 million, representing 4% sequential growth. The company also announced it has agreed in principle to a device financing facility with Rand Merchant Bank to support its South African National Treasury contract and hardware-as-a-service model.
Term
Q2 2027
“Q2 results demonstrate disciplined execution against our plan, with record revenue of $115.7 million and sequential margin improvement. Continued momentum across three differentiated growth engines - On-Site, AI Video, and IoT & Connected Services, combined with our major South African contract progressing ahead of our original expectations, reinforces that we are on track to deliver on our full-year objectives.”
Steve Towe, CEO of Powerfleet
“Services revenue grew 7% year-over-year, underscoring the strength of our services-led business. The device financing facility is designed to fund our largest growth opportunity as it scales. We remain on track to deliver our full-year guidance and targeted exit run-rate of $495 million and 27% EBITDA margins heading into next fiscal year.”
Paul Lalljie, President and Chief Financial Officer of Powerfleet